Skip to main content
SpringerLink
Log in

Benefits Versus Profits

Has Ihe Orphan Drug Act Gone Too Far?

  • Guest Editorial
  • The Orphan Drug Act
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Aslbury CH. The Orphan Drug Act: The first seven years. Journal of the American Medical Assodation 265: 893–897, 1991

    Article  Google Scholar 

  • DiMasi JA, Hansen RW, Grabowski HG,et al. The cost of innovation in the pharmaceutical industry. Journal of Health Economics 10:107–142, 1992

    Article  Google Scholar 

  • DiMasi JA. Hansen RW, Grabowski HO, et al. Implementation of the Orphan Drug Act: 1983-1991, Food and Law Journal 41 (4):363–404,1992

    Google Scholar 

  • Fuchs YR. Health care and the United States economic system: an essay in abnormal physiology. Milbank Memorial Fund Quarterly 50:211–237,1972

    Article  PubMed  CAS  Google Scholar 

  • Garber AM, Clarke AE, Goldman OP, Gluck ME. Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease. US Congress Office of Technology Assessment OTA-BP-H-194. US Government Printing Office, Washington,October, 1992

    Google Scholar 

  • Hansen R. The pharmaceutical development process: estimates of development costs and times and tile effect of proposed regulatory changes. Issues in Pharmaceutical Economics. R.A. Chien (Ed.),Lexington, MA, DC Heath and Company. 1979

    Google Scholar 

  • Pharmaceutical Manufscturers Association. Industry perspective:the Orphan Drug Act, Pharmaceutical Manufacturers Association, Washington, July. 1991

    Google Scholar 

  • Shulman S, Bienz-Tadmor B, Son Seo, et al. Implementation of the Orphan Drug Act: 1983-1991. Food and Law Journal 47 (4): 363–404, 1992

    Google Scholar 

  • US Congress Office of Technology Assessment. Pharmaceutical R&D:costs,risks, and rewards. OTA-H-522. US Government Printing Office, Washington. February, 1993

    Google Scholar 

  • Weisbrod BA. The health care quadrilemma: an essay on technological change. insurance, quality of care, and cost containment. Journal of Economic Literature 29: 523–552, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palo Alto Department of Veterans Affairs Medical Center, Stanford University School of Medicine, and Center for Advanced Study in the Behavioral Sciences, 204 Junipero Serra Boukvard, Stanford, California, 94305, USA

    Alan M. Garber

Authors
  1. Alan M. Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garber, A.M. Benefits Versus Profits. Pharmacoeconomics 5, 88–92 (1994). https://doi.org/10.2165/00019053-199405020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199405020-00002

Keywords

Search

Navigation